Integra LifeSciences (NASDAQ:IART) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Integra LifeSciences (NASDAQ:IART) issued its quarterly earnings data on Wednesday. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08, FiscalAI reports. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The firm had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences updated its Q3 2026 guidance to 0.530-0.610 EPS and its FY 2026 guidance to 2.400-2.500 EPS.

Here are the key takeaways from Integra LifeSciences’ conference call:

• Second-quarter execution improved: Revenue reached $419 million, up 0.7% organically, while adjusted EPS rose 24% year over year to $0.56 and exceeded the company’s guidance range. Gross margin expanded 60 basis points and adjusted EBITDA margin increased 160 basis points, supported by manufacturing efficiencies, lower remediation spending, and cost initiatives.
• Integra reaffirmed its 2026 organic revenue growth outlook of 0.8%-3.3% and adjusted EPS guidance of $2.40-$2.50, but lowered reported revenue expectations to $1.654-$1.695 billion because of foreign-ex exchange impacts. Potentially higher second-half interest expense from a planned refinancing is expected to be offset by tariff benefits and additional cost savings.
• Supply and product-relaunch milestones advanced: Manufacturing restarted at the Braintree facility, with inventory being built for a phased fourth-quarter SurgiMend relaunch. PriMatrix revenue has recovered to slightly above 50% of pre-recall levels, while DuraSorb continues to deliver double-digit growth.
• The company expects longer-term growth from potential PMA approvals for SurgiMend and DuraSorb in implant-based breast reconstruction, with SurgiMend targeted for earlier 2027 and DuraSorb later in 2027, subject to FDA inspections and approval.
• Tissue Reconstruction revenue declined 2% organically in the quarter, with Integra Skin facing a difficult comparison and MicroMatrix pressured by new competitors. ENT revenue also fell by low single digits as sinus-balloon reimbursement pressure outweighed growth in MicroFrance instruments.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock traded down $2.15 during midday trading on Wednesday, hitting $17.61. The company had a trading volume of 979,089 shares, compared to its average volume of 896,807. The stock has a market cap of $1.37 billion, a PE ratio of -2.75, a P/E/G ratio of 1.35 and a beta of 1.22. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $20.49. The business’s 50 day simple moving average is $17.61 and its two-hundred day simple moving average is $13.41. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Citigroup reaffirmed a “neutral” rating and set a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Wells Fargo & Company increased their price target on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Truist Financial upped their price target on shares of Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Finally, BMO Capital Markets initiated coverage on Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price objective on the stock. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $18.43.

Integra LifeSciences News Roundup

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra reported adjusted earnings of $0.56 per share, exceeding the $0.48 analyst consensus and increasing from $0.45 a year earlier. Revenue of $418.76 million was also slightly above the $417.54 million consensus. Integra LifeSciences Q2 Earnings Top Estimates
• Positive Sentiment: Third-quarter guidance calls for EPS of $0.53-$0.61 and revenue of $410 million-$425 million, with the respective midpoints slightly above current analyst estimates of $0.56 per share and $417.3 million. Integra LifeSciences Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Integra maintained a generally in-line full-year outlook, projecting 2026 EPS of $2.40-$2.50 versus the $2.45 consensus and revenue of approximately $1.7 billion. The guidance does not provide a clear upward revision to estimates. Integra Q2 Earnings Key Metrics Versus Estimates
• Negative Sentiment: The company continues to report a negative net margin, which may temper enthusiasm despite the quarterly earnings beat. The market’s lower reaction indicates investors may have been looking for stronger full-year guidance or more evidence of sustained profitability. Integra LifeSciences Second Quarter 2026 Financial Results

Institutional Trading of Integra LifeSciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Osaic Holdings Inc. increased its holdings in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares during the period. State of Tennessee Department of Treasury raised its position in shares of Integra LifeSciences by 7.9% during the fourth quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after buying an additional 1,964 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Integra LifeSciences by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after buying an additional 1,975 shares during the period. Capital Fund Management S.A. grew its position in Integra LifeSciences by 5.7% during the third quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock worth $535,000 after buying an additional 1,997 shares in the last quarter. Finally, Global Retirement Partners LLC bought a new position in Integra LifeSciences during the fourth quarter valued at about $25,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.